Andere talen Celldex Therapeutics, Inc.

Aandelen

CLDX

US15117B2025

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
36,26 ^USD	-2,05%		-5,89%	-8,57%

17/04	Celldex Therapeutics, Inc. Kondigt de voltooiing aan van de inschrijving voor de Fase 2-studie met barzolvolimab bij patiënten met chronische induceerbare urticaria	CI
28/02	Celldex Therapeutics doet voorstel voor $250 miljoen uitgeschreven gewone aandelen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17/04
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	17/04
Celldex Therapeutics : Corporate Presentation	17/04
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	08/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares	06/03
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference	06/03
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	05/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	05/03
Celldex Therapeutics Prices $400.4 Million Common Stock Offering	01/03
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock	01/03
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	28/02
Celldex Therapeutics Announces Proposed Public Offering of Common Stock	28/02
Sector Update: Health Care Stocks Weaker Monday Afternoon	26/02
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	26/02
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	26/02
Sector Update: Health Care Stocks Mixed Premarket Monday	26/02
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	26/02
Celldex: Q4 Earnings Snapshot	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Celldex Therapeutics, Inc.

Aandelen

CLDX

US15117B2025

Andere talen

Filters